Volume 85, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



A Phase I/II observer-blind, randomized, controlled trial evaluated the safety and immunogenicity of a dengue virus (DENV) vaccine candidate in healthy Thai infants (aged 12–15 months) without measurable pre-vaccination neutralizing antibodies to DENV and Japanese encephalitis virus. Fifty-one subjects received two doses of either DENV ( = 34; four received 1/10th dose) or control vaccine ( = 17; dose 1, live varicella; dose 2, type b). After each vaccine dose, adverse events (AEs) were solicited for 21 days, and non-serious AEs were solicited for 30 days; serious AEs (SAEs) were recorded throughout the study. Laboratory safety assessments were performed at 10 and 30 days; neutralizing antibodies were measured at 30 days. The DENV vaccine was well-tolerated without any related SAEs. After the second dose, 85.7% of full-dose DENV vaccinees developed at least trivalent and 53.6% developed tetravalent neutralizing antibodies ≥ 1:10 to DENV (control group = 0%). This vaccine candidate, therefore, warrants continued development in this age group (NCT00322049; clinicaltrials.gov).


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Forattini OP, , 2003. Epidemiology and phylogenetic relationships of dengue viruses. Dengue Bull 27: 9194. [Google Scholar]
  2. Monath TP, , 1994. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 91: 23952400.[Crossref] [Google Scholar]
  3. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A, , 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 29.[Crossref] [Google Scholar]
  4. Chaudhry S, Swaminathan S, Khanna N, , 2006. Viral genetics as a basis of dengue pathogenesis. Dengue Bull 30: 121132. [Google Scholar]
  5. Pediatric Dengue Vaccine Initiative (PDVI), 2010. Global Burden of Dengue. Available at: http://www.pdvi.org/about_dengue/GBD.asp. Accessed April 12, 2010. [Google Scholar]
  6. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott RM, Burke DS, Hoke CH, Innis BL, Vaughn DW, , 2003. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 68: 191202. [Google Scholar]
  7. World Health Organization, 2009. Fact Sheet Number 117. Geneva, Switzerland: World Health Organization. [Google Scholar]
  8. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, , 2007. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518528.[Crossref] [Google Scholar]
  9. DeRoeck D, Deen J, Clemens JD, , 2003. Policymakers' views on dengue fever/dengue haemorrhagic fever and the need for dengue vaccines in four southeast Asian countries. Vaccine 22: 121129.[Crossref] [Google Scholar]
  10. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH, Jr, 2003. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 69: 1216. [Google Scholar]
  11. Innis BL, Eckels KH, , 2003. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69: 14. [Google Scholar]
  12. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak RJ, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Berrera R, Jarman RG, Chawachalasai W, Mammen MP, Jr, 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78: 426433. [Google Scholar]
  13. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R, , 2009. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 5: 3340.[Crossref] [Google Scholar]
  14. Nutrition Division, Department of Health, Ministry of Public Health, 1999. National Growth References for Thai Children Under 20 Years of Age. Bangkok, Thailand: War Veterans Organization, 2883. [Google Scholar]
  15. Russell PK, Nisalak A, Suhhavachana P, Vivona S, , 1967. A plaque reduction test for dengue neutralization antibodies. J Immunol 99: 285290. [Google Scholar]
  16. Klungthong C, Gibbons RV, Thaisomboonsuk B, Nisalak A, Kalayanarooj S, Thirawuth V, Nutkumhang N, Mammen MP, Jr Jarman RG, , 2007. Dengue virus detection using whole blood for reverse transcriptase PCR and virus isolation. J Clin Microbiol 45: 24802485.[Crossref] [Google Scholar]
  17. Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V, , 2008. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods 153: 16.[Crossref] [Google Scholar]
  18. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH, Jr, 1989. An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 40: 418427. [Google Scholar]
  19. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical Dictionary for Regulatory Activities and Maintenance and Support Services Organization. Version 14.0 01, March 2011. Available at: http://www.meddramsso.com. Accessed May 26, 2011. [Google Scholar]
  20. Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, Polprasert N, Aree C, Vaughn DW, Ho C, Nisalak A, , 2002. Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 69: 123128. [Google Scholar]

Data & Media loading...

  • Received : 08 Sep 2010
  • Accepted : 02 May 2011
  • Published online : 01 Aug 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error